Annals of Hematology

, Volume 89, Issue 10, pp 1029–1033

Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab

  • Jens Marcus Chemnitz
  • Jens Uener
  • Michael Hallek
  • Christof Scheid
Original Article

DOI: 10.1007/s00277-010-0968-3

Cite this article as:
Chemnitz, J.M., Uener, J., Hallek, M. et al. Ann Hematol (2010) 89: 1029. doi:10.1007/s00277-010-0968-3

Abstract

Rituximab may be used to treat patients with thrombotic thrombocytopenic purpura (TTP) refractory to plasma exchange or recurrent disease. While initial response rates are reported to be high, long-term follow-up data of patients treated with rituximab are not available to date, however important to estimate the safety and benefit of this treatment. Twelve patients with non-familial idiopathic TTP refractory to plasma exchange or with recurrent disease treated with rituximab between 2000 and 2008 were reexamined. The median follow-up was 49.6 months, ranging from 11 to 97 months. All patients achieved initial complete remission after application of rituximab. During follow-up, nine patients remained disease-free and three patients suffered from recurrent disease. All patients with recurrent disease responded to subsequent rituximab therapy. No long-term side effects were noted during the follow-up period. In conclusion, rituximab represents an effective second-line treatment option in relapsing or refractory TTP. Still, patients need to be closely monitored for relapses with extended follow-up.

Keywords

TTP Treatment Rituximab Follow-up 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Jens Marcus Chemnitz
    • 1
    • 2
  • Jens Uener
    • 1
  • Michael Hallek
    • 1
  • Christof Scheid
    • 1
  1. 1.Department I of Internal MedicineUniversity of CologneCologneGermany
  2. 2.Department I of Internal MedicineUniversity Hospital of CologneCologneGermany

Personalised recommendations